-
-
12-lead ECG obtained from a 50-year old African American man with hypertension and chest pain.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
-
Though recent conflicting studies and commentaries have thoroughly confused the issue, the take-home message for infection control professionals which passes muster with all but the most strident critics is that the elderly should be immunized against seasonal influenza. Period.
-
Regardless of the current controversy regarding the efficacy of seasonal influenza vaccination in the elderly, it seems a given that seniors will fare much worse should a pandemic strain arise that eludes an immune response in all ages. But under closer scrutiny, that logic does not hold.
-
All the planets appear to be lining up to make a persuasive "business case" for infection control.
-
Hospitalizations related to methicillin-resistant Staphylococcus aureus (MRSA) infections more than doubled, from 127,000 to nearly 280,000, between 1999 and 2005, according to a new study.
